Brokerages Set Senseonics Holdings, Inc. (NYSE:SENS) PT at $1.55

Shares of Senseonics Holdings, Inc. (NYSE:SENS) have been assigned an average recommendation of “Buy” from the five ratings firms that are covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $1.5375.

SENS has been the subject of a number of analyst reports. TD Cowen initiated coverage on shares of Senseonics in a report on Tuesday, July 15th. They issued a “buy” rating and a $1.25 price objective for the company. Wall Street Zen raised shares of Senseonics to a “sell” rating in a report on Monday, May 12th. Barclays initiated coverage on shares of Senseonics in a report on Wednesday. They issued an “overweight” rating and a $1.50 price objective for the company. Lake Street Capital raised shares of Senseonics to a “strong-buy” rating in a report on Thursday, July 17th. Finally, HC Wainwright reissued a “buy” rating and issued a $1.40 price objective (up previously from $1.10) on shares of Senseonics in a report on Tuesday, July 8th.

Senseonics Trading Down 0.1%

Shares of SENS opened at $0.46 on Wednesday. The company has a current ratio of 2.47, a quick ratio of 2.38 and a debt-to-equity ratio of 59.17. Senseonics has a 12-month low of $0.25 and a 12-month high of $1.40. The firm has a 50-day moving average price of $0.50 and a 200 day moving average price of $0.61. The firm has a market capitalization of $374.35 million, a P/E ratio of -3.53 and a beta of 0.88.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Millennium Management LLC lifted its position in shares of Senseonics by 299.0% during the fourth quarter. Millennium Management LLC now owns 1,088,029 shares of the company’s stock worth $569,000 after purchasing an additional 815,332 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Senseonics during the fourth quarter worth about $720,000. Two Sigma Investments LP acquired a new stake in shares of Senseonics during the fourth quarter worth about $36,000. Raymond James Financial Inc. acquired a new stake in shares of Senseonics during the fourth quarter worth about $26,000. Finally, Cambridge Investment Research Advisors Inc. lifted its position in shares of Senseonics by 679.9% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 289,919 shares of the company’s stock worth $190,000 after purchasing an additional 252,745 shares in the last quarter. Institutional investors and hedge funds own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.